Biocon Q4FY26: Income ₹4,569 Cr, EBITDA ₹1,073 Cr

Results announcement and what changed

Biocon Limited (BSE: 532523, NSE: BIOCON) reported consolidated financial results for the quarter and year ended March 31, 2026. The company’s Q4FY26 performance showed higher income and a stronger year-on-year EBITDA comparison on an adjusted base, alongside a rise in profit before exceptional items. For FY26, Biocon reported double-digit growth in revenue from operations and total income, with improved like-to-like margins highlighted in the company commentary. The update is based on the company’s regulatory filing with the stock exchanges.

The headline numbers for Q4FY26 included total income of ₹4,569 crore and revenue from operations of ₹4,517 crore. EBITDA for the quarter stood at ₹1,073 crore with an EBITDA margin of 23%. Net profit before exceptional items was ₹179 crore, while reported net profit was ₹126 crore after accounting for exceptional items.

Q4FY26: segment mix and consolidated performance

Biocon’s Q4FY26 consolidated segment revenues (as reported in the financial highlights) were led by Biosimilars at ₹2,756 crore, followed by Generics at ₹847 crore, and CRDMO/Research Services at ₹1,037 crore. Inter-segment revenue was reported at (₹122) crore for the quarter, which reconciles segment totals to consolidated revenue from operations.

The company’s financial commentary stated that operating revenue rose 10% year-on-year after adjusting for one-time generic lenalidomide sales in Q4FY25. EBITDA was ₹1,073 crore, and net profit before exceptional items was ₹179 crore. Net R&D expenses in the quarter were ₹277 crore.

A key bridge item for bottom line comparability was the exceptional items impact. Biocon disclosed that exceptional items during Q4FY26 amounted to (₹53) crore, resulting in reported net profit of ₹126 crore for the quarter.

FY26: income, profitability and margin profile

For the full year FY26, Biocon reported total income of ₹17,270 crore and revenue from operations of ₹16,927 crore. EBITDA for the year was ₹3,798 crore with an EBITDA margin of 22%. Net profit before exceptional items was ₹436 crore, and reported net profit was ₹386 crore.

The company commentary noted that operating revenue rose 13% year-on-year in FY26 after adjusting for one-time generic lenalidomide sales in FY25. It also stated that the EBITDA margin was up 200 basis points on a like-to-like basis.

Exceptional items for FY26 were disclosed at (₹50) crore, which the company said resulted in reported net profit of ₹386 crore for the year.

Segment snapshot for FY26

In FY26, Biosimilars revenue was ₹10,431 crore, Generics revenue was ₹3,168 crore, and CRDMO/Research Services revenue was ₹3,739 crore. Inter-segment was reported at (₹411) crore for FY26, reconciling the segment totals to revenue from operations.

The year-on-year growth rates shown in the company’s table were 16% for Biosimilars, 17% for Generics (marked with an asterisk in the table), and 3% for CRDMO/Research Services. These segment movements explain the broad-based revenue increase in FY26, with Biosimilars remaining the largest contributor to consolidated operations.

Key financial table: Q4FY26 vs FY26

Dividend recommendation and shareholder calendar

Biocon’s Board of Directors recommended a final dividend of Re. 0.50 per share, stated as 10% of the face value, for the financial year ended March 31, 2026. Separately, the company also communicated that its board meeting was scheduled for Thursday, May 7, 2026, to approve and take on record audited standalone and consolidated financial results for Q4 and FY26, and to consider dividend recommendation.

An earnings conference call was scheduled for Friday, May 8, 2026 at 09:00 hrs IST, to be conducted via the Zoom platform. The trading window for company securities was stated to be closed from April 1, 2026 to May 9, 2026 (both days inclusive), and set to reopen on May 10, 2026.

The stock exchange communication mentioned investor relations contact details (Prashant Nair) and indicated the intimation was signed by Rajesh U. Shanoy, Company Secretary and Compliance Officer, and filed with BSE and NSE on April 23, 2026.

Recent quarterly context from Q3FY26

As background, the company also reported Q3FY26 consolidated revenue from operations of ₹4,173 crore and total revenue of ₹4,290 crore. EBITDA in Q3FY26 was ₹951 crore with an EBITDA margin of 22%. Net R&D expenses were ₹249 crore, and profit before tax before exceptional items was ₹226 crore.

In Q3FY26, net profit before exceptional items was ₹124 crore and reported net profit was ₹144 crore, as per the company’s Q3 highlights. Segment-wise revenue in Q3FY26 was reported as Biosimilars ₹2,497 crore, Generics ₹851 crore, and CRDMO/Research Services ₹917 crore, with inter-segment at (₹92) crore.

Market and investor takeaways based on disclosed numbers

The FY26 data points show Biocon’s revenue growth was supported primarily by Biosimilars scale-up, with Generics also expanding year-on-year in the reported table. EBITDA margins were reported at 23% in Q4FY26 and 22% for FY26, indicating operating profitability remained broadly stable at a consolidated level across the year.

Profit comparability in the quarter and full year is influenced by exceptional items, which the company quantified for Q4FY26 and FY26. Investors typically track both reported profit and profit before exceptional items for a cleaner view of operating performance, especially when exceptional items are material to quarterly net profit.

Conclusion

Biocon closed FY26 with total income of ₹17,270 crore and EBITDA of ₹3,798 crore, while Q4FY26 total income stood at ₹4,569 crore with EBITDA of ₹1,073 crore. The company has already laid out the immediate next steps through its board approval process, earnings call scheduled for May 8, 2026, and the trading window reopening date of May 10, 2026.